MA28994B1 - Composition immunogene - Google Patents
Composition immunogeneInfo
- Publication number
- MA28994B1 MA28994B1 MA29821A MA29821A MA28994B1 MA 28994 B1 MA28994 B1 MA 28994B1 MA 29821 A MA29821 A MA 29821A MA 29821 A MA29821 A MA 29821A MA 28994 B1 MA28994 B1 MA 28994B1
- Authority
- MA
- Morocco
- Prior art keywords
- immunogenic composition
- immunogenic
- composition
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/085—Staphylococcus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
- C07K16/1267—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria
- C07K16/1271—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria from Micrococcaceae (F), e.g. Staphylococcus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/116—Polyvalent bacterial antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/646—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB0421081A GB0421081D0 (en) | 2004-09-22 | 2004-09-22 | Immunogenic composition |
GB0421078A GB0421078D0 (en) | 2004-09-22 | 2004-09-22 | Immunogenic composition |
GB0421079A GB0421079D0 (en) | 2004-09-22 | 2004-09-22 | Immunogenic composition |
GB0421082A GB0421082D0 (en) | 2004-09-22 | 2004-09-22 | Immunogenic composition |
GB0503143A GB0503143D0 (en) | 2005-02-15 | 2005-02-15 | Immunogenic composition |
Publications (1)
Publication Number | Publication Date |
---|---|
MA28994B1 true MA28994B1 (fr) | 2007-11-01 |
Family
ID=36000843
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA29821A MA28994B1 (fr) | 2004-09-22 | 2007-04-11 | Composition immunogene |
MA29822A MA28995B1 (fr) | 2004-09-22 | 2007-04-11 | Composition immunogene |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA29822A MA28995B1 (fr) | 2004-09-22 | 2007-04-11 | Composition immunogene |
Country Status (18)
Country | Link |
---|---|
US (6) | US20080095777A1 (fr) |
EP (9) | EP2305294B1 (fr) |
JP (5) | JP2008513406A (fr) |
KR (4) | KR101505496B1 (fr) |
CN (2) | CN102657855B (fr) |
AU (3) | AU2005287502B2 (fr) |
BR (3) | BR122016029840B1 (fr) |
CA (4) | CA2983954C (fr) |
ES (4) | ES2472441T3 (fr) |
HK (1) | HK1155658A1 (fr) |
IL (4) | IL181825A0 (fr) |
MA (2) | MA28994B1 (fr) |
MX (2) | MX2007003400A (fr) |
NO (2) | NO20071609L (fr) |
NZ (4) | NZ582441A (fr) |
RU (1) | RU2402347C2 (fr) |
WO (3) | WO2006032475A2 (fr) |
ZA (1) | ZA200702224B (fr) |
Families Citing this family (90)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2648046T3 (es) | 2002-11-12 | 2017-12-28 | The Brigham And Women's Hospital, Inc. | Vacuna de polisacárido para infecciones estafilocócicas |
EP2305294B1 (fr) | 2004-09-22 | 2015-04-01 | GlaxoSmithKline Biologicals SA | Composition immunogène pour la vaccination contre des staphylocoques |
EP1802335A2 (fr) | 2004-10-21 | 2007-07-04 | Wyeth a Corporation of the State of Delaware | Compositions immunogenes a base de polypeptides antigenes de staphylococcus epidermidis |
KR20070085457A (ko) * | 2004-10-25 | 2007-08-27 | 더 유니버시티 오브 웨스턴 온타리오 | 스태필로코쿠스 아우레우스의 철에 의해 조절되는 표면결정인자 IsdA, IsdB, 및 IsdC 기재 백신,조성물 및 방법 |
US20060228368A1 (en) * | 2005-04-07 | 2006-10-12 | Nabi Biopharmaceuticals | Method of protecting against staphylococcal infection |
PT2351578T (pt) * | 2005-06-27 | 2017-04-07 | Glaxosmithkline Biologicals Sa | Processo para o fabrico de vacinas |
GB0526038D0 (en) * | 2005-12-21 | 2006-02-01 | Glaxosmithkline Biolog Sa | Immunogenic composition |
CA2637598A1 (fr) * | 2006-01-18 | 2007-02-14 | University Of Chicago | Compositions et procedes se rapportant a des proteines de bacteries staphylococciques |
KR101541383B1 (ko) * | 2006-03-30 | 2015-08-03 | 글락소스미스클라인 바이오로지칼즈 에스.에이. | 면역원성 조성물 |
WO2007123386A1 (fr) * | 2006-04-24 | 2007-11-01 | Sigma Alimentos, S.A. De C.V. | Procédé de détection et de quantification multiple et simultanée de pathogènes par réaction en chaîne par polymérase en temps réel |
GB0610776D0 (en) * | 2006-05-31 | 2006-07-12 | Univ Bath | Novel applications for staphylococcus aureus Sbi protein |
US20180221466A9 (en) * | 2006-06-12 | 2018-08-09 | Glaxosmithkline Biologicals S.A. | Use of alpha-toxin for treating and preventing staphylococcus infections |
CN101466406B (zh) * | 2006-06-12 | 2012-06-27 | 葛兰素史密斯克蓝生物品公司 | α-毒素在治疗和预防葡萄球菌感染上的用途 |
GB0700136D0 (en) * | 2007-01-04 | 2007-02-14 | Glaxosmithkline Biolog Sa | Process for manufacturing vaccines |
EP1987836B1 (fr) * | 2007-05-04 | 2011-12-21 | Martin Krönke | Vaccin de protection contre le staphylococcus aureus basé sur des protéines liées à la paroi cellulaire |
US8146781B2 (en) * | 2007-08-09 | 2012-04-03 | Huhtamaki, Inc. | Dispenser for viscous condiments |
WO2009023164A2 (fr) * | 2007-08-10 | 2009-02-19 | President And Fellows Of Harvard College | Induction de l'immunité des muqueuses |
WO2009029831A1 (fr) * | 2007-08-31 | 2009-03-05 | University Of Chicago | Procédés et compositions associées pour immuniser contre des maladies et des états staphylococciques des poumons |
US9181329B2 (en) | 2007-08-31 | 2015-11-10 | The University Of Chicago | Methods and compositions related to immunizing against Staphylococcal lung diseases and conditions |
WO2009111337A1 (fr) | 2008-03-03 | 2009-09-11 | Irm Llc | Composés et compositions servant de modulateurs de l’activité des tlr |
ES2556354T3 (es) * | 2008-03-31 | 2016-01-15 | Otsuka Pharmaceutical Co., Ltd. | Método para la detección de neumococos |
EA201001478A1 (ru) * | 2008-04-16 | 2011-06-30 | Глаксосмитклайн Байолоджикалс С.А. | Вакцина |
TWI551295B (zh) | 2008-04-18 | 2016-10-01 | 英特威特國際股份有限公司 | 防備胞內勞森菌(Lawsonia intracellularis)用疫苗 |
CN105085349B (zh) | 2008-07-21 | 2018-02-09 | 布赖汉姆妇女医院 | 与合成的β‑1,6 葡糖胺寡糖相关的方法和组合物 |
WO2010014304A1 (fr) | 2008-07-29 | 2010-02-04 | University Of Chicago | Compositions et procédés apparentés à des protéines de bactérie staphylococcique |
CA2738793A1 (fr) * | 2008-09-30 | 2010-04-08 | University Of Maryland, Baltimore | Vaccin protecteur contre des biofilms de staphylococcus aureus renfermant des immunogenes associes a la paroi cellulaire |
EP2208787A1 (fr) * | 2009-01-19 | 2010-07-21 | Université de Liège | Polypeptide d'alpha-hémolysine recombinant de Staphylococcus aureus doté d'une suppression dans le domaine de la branche et des insertions de séquences hétérologues |
US8101190B2 (en) * | 2009-03-03 | 2012-01-24 | Ingen Biosciences | Method for diagnosing staphylococcal infections |
KR101773368B1 (ko) | 2009-04-03 | 2017-08-31 | 유니버시티 오브 시카고 | 단백질 A(SpA) 변이체와 관련된 조성물 및 방법 |
AU2010258677B2 (en) | 2009-06-10 | 2016-10-06 | Glaxosmithkline Biologicals S.A. | Benzonaphthyridine-containing vaccines |
TWI469789B (zh) * | 2009-06-22 | 2015-01-21 | Wyeth Llc | 金黃色葡萄球菌抗原之免疫原性組合物 |
RU2531234C2 (ru) * | 2009-06-22 | 2014-10-20 | ВАЙЕТ ЭлЭлСи | КОНЪЮГАТ ПОЛИСАХАРИД-БЕЛОК ДЛЯ ИНДУЦИРОВАНИЯ ИММУННОГО ОТВЕТА И ЗАЩИТЫ ПРОТИВ ИНФЕКЦИИ Staphylococcus aureus, СПОСОБЫ ПОЛУЧЕНИЯ КОНЪЮГАТА (ВАРИАНТЫ), КОМПОЗИЦИЯ, СОДЕРЖАЩАЯ КОНЪЮГАТ И СПОСОБЫ ИНДУЦИРОВАНИЯ ИММУННОГО ОТВЕТА И ПРЕДОТВРАЩЕНИЯ ИНФЕКЦИИ Staphylococcus aureus |
WO2012122533A2 (fr) * | 2011-03-10 | 2012-09-13 | The University Of Chicago | Compositions et procédés liés à des anticorps contre les protéines staphylococciques isda ou isdb |
WO2011017101A2 (fr) * | 2009-07-27 | 2011-02-10 | Fina Biosolutions, Llc | Procédé de production de vaccins à protéine-carbohydrate à niveau réduit de carbohydrate libre |
GB0913680D0 (en) | 2009-08-05 | 2009-09-16 | Glaxosmithkline Biolog Sa | Immunogenic composition |
GB0913681D0 (en) * | 2009-08-05 | 2009-09-16 | Glaxosmithkline Biolog Sa | Immunogenic composition |
CN102844047B (zh) | 2009-09-02 | 2017-04-05 | 诺华股份有限公司 | 含tlr活性调节剂的免疫原性组合物 |
TWI445708B (zh) | 2009-09-02 | 2014-07-21 | Irm Llc | 作為tlr活性調節劑之化合物及組合物 |
JP2013506651A (ja) | 2009-09-30 | 2013-02-28 | ノバルティス アーゲー | Staphylococcus.aureus5型および8型莢膜多糖の結合体 |
PT2493498T (pt) * | 2009-10-30 | 2017-05-24 | Glaxosmithkline Biologicals Sa | Purificação de sacáridos capsulares de staphylococcus aureus tipo 5 e tipo 8 |
WO2011057148A1 (fr) | 2009-11-05 | 2011-05-12 | Irm Llc | Composés et compositions permettant de moduler l'activité des tlr-7 |
JP6091214B2 (ja) * | 2009-11-16 | 2017-03-08 | ザ ヘンリー エム.ジャクソン ファウンデイション フォー ザ アドバンスメント オブ ミリタリー メディスン,インコーポレイティド | ポリ−グリセロールリン酸をベースにした抗グラム陽性細菌ワクチン |
AU2010339921B2 (en) | 2009-12-15 | 2016-08-11 | Glaxosmithkline Biologicals S.A. | Homogeneous suspension of immunopotentiating compounds and uses thereof |
BR122022002136B1 (pt) | 2009-12-17 | 2022-08-23 | Fina Biosolutions, Llc | Processo de conjugação de carboidratos na preparação de vacinas conjugadas e suas respectivas vacinas |
EA031379B1 (ru) | 2010-03-23 | 2018-12-28 | Новартис Аг | Соединения (липопептиды на основе цистеина) и композиции в качестве агонистов tlr2, применяемые для лечения инфекционных, воспалительных, респираторных и других заболеваний |
JP2013523818A (ja) | 2010-04-05 | 2013-06-17 | ザ・ユニバーシティー・オブ・シカゴ | 免疫反応のエンハンサーとしてのプロテインA(SpA)抗体に関連する組成物および方法 |
US8383783B2 (en) | 2010-04-23 | 2013-02-26 | Serum Institute Of India, Ltd. | Simple method for simultaneous removal of multiple impurities from culture supernatants to ultralow levels |
CN102268444B (zh) * | 2010-06-03 | 2015-05-13 | 中国人民解放军军事医学科学院生物工程研究所 | 金黄色葡萄球菌截短SasA蛋白在大肠杆菌中的表达及应用 |
CN103037885B (zh) | 2010-07-02 | 2015-08-26 | 芝加哥大学 | 与蛋白A(SpA)变体相关的组合物和方法 |
US9192661B2 (en) | 2010-07-06 | 2015-11-24 | Novartis Ag | Delivery of self-replicating RNA using biodegradable polymer particles |
US20130115209A1 (en) * | 2010-07-15 | 2013-05-09 | Tessie B. McNeely | Protective vaccine based on staphylococcus aureus protein sa2412 |
JP5793194B2 (ja) | 2010-09-09 | 2015-10-14 | ザ・ユニバーシティ・オブ・シカゴThe University Of Chicago | 感染防御ブドウ球菌抗原が関与する方法および組成物 |
WO2012065034A1 (fr) | 2010-11-12 | 2012-05-18 | Merck Sharp & Dohme Corp. | Vaccins à base de conjugués de peptide énolase, contre staphylococcus aureus |
EP2654784B1 (fr) | 2010-12-22 | 2016-12-07 | Wyeth LLC | Compositions immunogènes stables d'antigènes de staphylococcus aureus |
SG10201600899PA (en) * | 2011-02-08 | 2016-03-30 | Medimmune Llc | Antibodies that specifically bind staphylococcus aureus alpha toxin and methods of use |
JP2014507142A (ja) * | 2011-02-08 | 2014-03-27 | インテグレイテッド バイオセラピューティクス,インコーポレイテッド | α溶血素オリゴペプチドを含む免疫原性組成物 |
US8945588B2 (en) | 2011-05-06 | 2015-02-03 | The University Of Chicago | Methods and compositions involving protective staphylococcal antigens, such as EBH polypeptides |
BR112013032911A2 (pt) | 2011-06-19 | 2017-01-24 | Univ New York | leucotoxina e/d como um novo agente anti-inflamatório e microbicida |
LT3403669T (lt) | 2011-06-19 | 2020-10-12 | New York University | Staphylococcus aureus infekcijų ir giminingų būklių gydymo bei prevencijos būdai |
CA2845259A1 (fr) | 2011-08-15 | 2013-02-21 | The University Of Chicago | Compositions et procedes lies aux anticorps anti-proteine a du staphylocoque |
WO2013066731A2 (fr) | 2011-10-31 | 2013-05-10 | Merck Sharp & Dohme Corp. | Vaccin prophylactique à base de la protéine sa2451 de staphylococcus aureus |
CN102698260B (zh) * | 2012-04-20 | 2013-09-25 | 西北农林科技大学 | 预防山羊葡萄球菌乳房炎的亚单位疫苗的制备方法及应用 |
EP2844275B1 (fr) | 2012-04-26 | 2020-05-13 | University of Chicago | Antigènes des staphylocoques coagulase et leurs méthodes d'utilisation |
CA2910320A1 (fr) | 2012-04-26 | 2013-10-31 | University Of Chicago | Compositions et procedes associes a des anticorps qui neutralisent l'activite coagulase dans une maladie a staphylococcus aureus |
CA3187222A1 (fr) * | 2012-05-09 | 2013-11-14 | Contrafect Corporation | Prevention, degradation et traitement de biofilms par la lysine de bacteriophage |
WO2013184900A2 (fr) * | 2012-06-06 | 2013-12-12 | Sanofi Pasteur Biologics, Llc | Compositions immunogènes et procédés associés |
US9376487B2 (en) | 2012-07-10 | 2016-06-28 | Merck Sharp & Dohme Corp. | Protective vaccine based on Staphylococcus aureus SA2493 protein |
CN102993308B (zh) * | 2012-09-29 | 2014-11-05 | 重庆原伦生物科技有限公司 | 耐甲氧西林金黄色葡萄球菌(mrsa)疫苗重组蛋白抗原hi2及制备方法和应用 |
CN102898511B (zh) * | 2012-10-19 | 2014-05-07 | 重庆原伦生物科技有限公司 | 耐甲氧西林金黄色葡萄球菌重组基因工程疫苗候选抗原i12c制备中的纯化方法 |
CN103087198B (zh) * | 2013-01-21 | 2014-03-12 | 重庆原伦生物科技有限公司 | 耐甲氧西林金黄色葡萄球菌(mrsa)疫苗重组蛋白抗原i1c及制备方法和应用 |
EP2950819B1 (fr) | 2013-02-01 | 2018-03-28 | GlaxoSmithKline Biologicals SA | Administration intradermique de compositions immunologiques comprenant des agonistes des récepteurs de type toll |
CN103333254A (zh) * | 2013-06-21 | 2013-10-02 | 重庆原伦生物科技有限公司 | 耐甲氧西林金黄色葡萄球菌(mrsa)重组蛋白疫苗i1c的纯化方法 |
ES2754209T3 (es) | 2013-12-13 | 2020-04-16 | Stora Enso Oyj | Cartón multicapa |
CN105483138B (zh) * | 2016-01-22 | 2019-03-26 | 吉林大学 | 一种与致病力相关的灰霉病菌基因BcAtm1及其应用 |
JP7117244B2 (ja) * | 2016-02-12 | 2022-08-12 | ザ・ユニバーシティ・オブ・シカゴ | 黄色ブドウ球菌疾患の間にコアグラーゼ活性を中和する抗体に関連した組成物および方法 |
EP3530285B1 (fr) * | 2016-10-20 | 2023-08-09 | KM Biologics Co., Ltd. | PROCÉDÉ DE PRODUCTION D'UN VACCIN CONJUGÉ HIB UTILISANT DU PRP
DE POIDS MOLÉCULAIRE REDUIT |
CN106692963B (zh) * | 2016-12-28 | 2020-12-22 | 中国人民解放军军事医学科学院生物工程研究所 | 一种用于预防金黄色葡萄球菌感染和破伤风的联合疫苗 |
GB201721576D0 (en) * | 2017-12-21 | 2018-02-07 | Glaxosmithkline Biologicals Sa | Hla antigens and glycoconjugates thereof |
EA202091931A1 (ru) | 2018-02-12 | 2020-11-05 | Иниммьюн Корпорейшн | ЛИГАНДЫ Toll-ПОДОБНЫХ РЕЦЕПТОРОВ |
GB201802339D0 (en) * | 2018-02-13 | 2018-03-28 | Glaxosmithkline Biologicals Sa | Immunogenic composition |
CN109395072B (zh) * | 2018-10-30 | 2021-11-30 | 中国兽医药品监察所 | 一种腐败梭菌α毒素基因工程疫苗及其生产方法 |
CN110055276A (zh) * | 2019-01-28 | 2019-07-26 | 杨凌职业技术学院 | 一种金葡菌靶向抗菌肽细菌诱导型表达载体及其重组细胞 |
CN110892989B (zh) * | 2019-06-27 | 2023-03-14 | 内蒙古伊利实业集团股份有限公司 | 一种具有缓解便秘功能的副干酪乳杆菌et-22 |
CN112391304B (zh) * | 2019-08-15 | 2023-04-07 | 上海交通大学 | 副血链球菌f278及其用途 |
CN110590910A (zh) * | 2019-09-27 | 2019-12-20 | 黑龙江八一农垦大学 | 能够增强细胞免疫应答和抗感染作用的合成肽 |
CN111072775B (zh) * | 2019-12-26 | 2021-08-20 | 成都欧林生物科技股份有限公司 | 抗MntC蛋白抗体及其应用和包含其的试剂盒 |
CN111138551A (zh) * | 2020-01-15 | 2020-05-12 | 黑龙江八一农垦大学 | 一种预防金黄色葡萄球菌和白色念珠菌感染的atm融合蛋白的制备及应用 |
US20230087622A1 (en) * | 2020-01-29 | 2023-03-23 | The Jackson Laboratory | Bacterial admixtures |
US11473093B2 (en) | 2020-11-04 | 2022-10-18 | Eligo Bioscience | Cutibacterium acnes recombinant phages, method of production and uses thereof |
GB202205833D0 (en) | 2022-04-21 | 2022-06-08 | Glaxosmithkline Biologicals Sa | Bacteriophage |
Family Cites Families (113)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB116556A (en) | 1917-06-21 | 1918-06-20 | British Thomson Houston Co Ltd | Improvements in and relating to Dynamo Electric Machines. |
SE335780B (fr) * | 1964-09-14 | 1971-06-07 | Canadian Patents Dev | |
FR2227861B1 (fr) * | 1973-05-04 | 1976-07-02 | Anvar | |
JPS5452794A (en) | 1977-09-30 | 1979-04-25 | Kousaku Yoshida | Extracting of polysacchride from capusle containing epidermis staphylococus |
US4235877A (en) | 1979-06-27 | 1980-11-25 | Merck & Co., Inc. | Liposome particle containing viral or bacterial antigenic subunit |
US4372945A (en) | 1979-11-13 | 1983-02-08 | Likhite Vilas V | Antigen compounds |
IL61904A (en) | 1981-01-13 | 1985-07-31 | Yeda Res & Dev | Synthetic vaccine against influenza virus infections comprising a synthetic peptide and process for producing same |
US4356170A (en) | 1981-05-27 | 1982-10-26 | Canadian Patents & Development Ltd. | Immunogenic polysaccharide-protein conjugates |
US4603112A (en) | 1981-12-24 | 1986-07-29 | Health Research, Incorporated | Modified vaccinia virus |
US4769330A (en) | 1981-12-24 | 1988-09-06 | Health Research, Incorporated | Modified vaccinia virus and methods for making and using the same |
US4596556A (en) | 1985-03-25 | 1986-06-24 | Bioject, Inc. | Hypodermic injection apparatus |
GB8508845D0 (en) | 1985-04-04 | 1985-05-09 | Hoffmann La Roche | Vaccinia dna |
US4777127A (en) | 1985-09-30 | 1988-10-11 | Labsystems Oy | Human retrovirus-related products and methods of diagnosing and treating conditions associated with said retrovirus |
US5139941A (en) | 1985-10-31 | 1992-08-18 | University Of Florida Research Foundation, Inc. | AAV transduction vectors |
GB8702816D0 (en) | 1987-02-07 | 1987-03-11 | Al Sumidaie A M K | Obtaining retrovirus-containing fraction |
US5219740A (en) | 1987-02-13 | 1993-06-15 | Fred Hutchinson Cancer Research Center | Retroviral gene transfer into diploid fibroblasts for gene therapy |
US5320951A (en) | 1987-06-01 | 1994-06-14 | Hoeoek Magnus | Fibronectin binding protein as well as its preparation |
US4940460A (en) | 1987-06-19 | 1990-07-10 | Bioject, Inc. | Patient-fillable and non-invasive hypodermic injection device assembly |
US4941880A (en) | 1987-06-19 | 1990-07-17 | Bioject, Inc. | Pre-filled ampule and non-invasive hypodermic injection device assembly |
US4790824A (en) | 1987-06-19 | 1988-12-13 | Bioject, Inc. | Non-invasive hypodermic injection device |
DE10399032I1 (de) | 1987-08-28 | 2004-01-29 | Health Research Inc | Rekombinante Viren. |
WO1989001973A2 (fr) | 1987-09-02 | 1989-03-09 | Applied Biotechnology, Inc. | Virus variolique recombinant d'immunisation contre des antigenes associes a une tumeur |
US5339163A (en) | 1988-03-16 | 1994-08-16 | Canon Kabushiki Kaisha | Automatic exposure control device using plural image plane detection areas |
AP129A (en) | 1988-06-03 | 1991-04-17 | Smithkline Biologicals S A | Expression of retrovirus gag protein eukaryotic cells |
US4912094B1 (en) | 1988-06-29 | 1994-02-15 | Ribi Immunochem Research Inc. | Modified lipopolysaccharides and process of preparation |
SE8901687D0 (sv) | 1989-05-11 | 1989-05-11 | Alfa Laval Agri Int | Fibronectin binding protein as well as its preparation |
EP1645635A3 (fr) | 1989-08-18 | 2010-07-07 | Oxford Biomedica (UK) Limited | Retrovirus recombinants défectifs pour la réplication exprimant un palliatif |
US5064413A (en) | 1989-11-09 | 1991-11-12 | Bioject, Inc. | Needleless hypodermic injection device |
US5312335A (en) | 1989-11-09 | 1994-05-17 | Bioject Inc. | Needleless hypodermic injection device |
DE69031951T2 (de) | 1989-11-16 | 1998-08-13 | Cornell Res Foundation Inc | Transformation von tierischen Hautzellen mit hilfe von Partikeln |
FR2658432B1 (fr) | 1990-02-22 | 1994-07-01 | Medgenix Group Sa | Microspheres pour la liberation controlee des substances hydrosolubles et procede de preparation. |
SE466259B (sv) | 1990-05-31 | 1992-01-20 | Arne Forsgren | Protein d - ett igd-bindande protein fraan haemophilus influenzae, samt anvaendning av detta foer analys, vacciner och uppreningsaendamaal |
WO1992001070A1 (fr) | 1990-07-09 | 1992-01-23 | The United States Of America, As Represented By The Secretary, U.S. Department Of Commerce | Conditionnement a haute efficacite de virus adeno-associe mutant utilisant la suppression d'ambre |
MY109299A (en) | 1990-08-15 | 1996-12-31 | Virogenetics Corp | Recombinant pox virus encoding flaviviral structural proteins |
GB9106048D0 (en) | 1991-03-21 | 1991-05-08 | Smithkline Beecham Biolog | Vaccines |
US5173414A (en) | 1990-10-30 | 1992-12-22 | Applied Immune Sciences, Inc. | Production of recombinant adeno-associated virus vectors |
CA2059692C (fr) | 1991-01-28 | 2004-11-16 | Peter J. Kniskern | Vaccin conjugue de polysaccharide contre les pneumocoques |
CA2059693C (fr) | 1991-01-28 | 2003-08-19 | Peter J. Kniskern | Antigenes polysaccharides de streptococcus pneumoniae |
GB9105992D0 (en) | 1991-03-21 | 1991-05-08 | Smithkline Beecham Biolog | Vaccine |
DE69233013T2 (de) | 1991-08-20 | 2004-03-04 | The Government Of The United States Of America As Represented By The Secretary Of National Institute Of Health, Office Of Technology Transfer | Adenovirus vermittelter gentransfer in den gastrointestinaltrakt |
GB9118204D0 (en) | 1991-08-23 | 1991-10-09 | Weston Terence E | Needle-less injector |
JP4087896B2 (ja) * | 1991-11-22 | 2008-05-21 | ナビ・バイオフアーマシユテイカルズ | スタフィロコッカス・エピダーミジス関連i及びii型表面抗原 |
MY111880A (en) | 1992-03-27 | 2001-02-28 | Smithkline Beecham Biologicals S A | Hepatitis vaccines containing 3-0 deacylated monophosphoryl lipid a |
ES2143716T3 (es) | 1992-06-25 | 2000-05-16 | Smithkline Beecham Biolog | Composicion de vacuna que contiene adyuvantes. |
US5383851A (en) | 1992-07-24 | 1995-01-24 | Bioject Inc. | Needleless hypodermic injection device |
US5569189A (en) | 1992-09-28 | 1996-10-29 | Equidyne Systems, Inc. | hypodermic jet injector |
US5334144A (en) | 1992-10-30 | 1994-08-02 | Becton, Dickinson And Company | Single use disposable needleless injector |
CN1119026A (zh) | 1993-02-05 | 1996-03-20 | 史密丝克莱恩比彻姆有限公司 | 纤连蛋白结合蛋白;单克隆抗体以及它们对防止细菌粘附的应用 |
US5654186A (en) | 1993-02-26 | 1997-08-05 | The Picower Institute For Medical Research | Blood-borne mesenchymal cells |
SG48309A1 (en) | 1993-03-23 | 1998-04-17 | Smithkline Beecham Biolog | Vaccine compositions containing 3-0 deacylated monophosphoryl lipid a |
US6015686A (en) | 1993-09-15 | 2000-01-18 | Chiron Viagene, Inc. | Eukaryotic layered vector initiation systems |
JP3828145B2 (ja) | 1993-09-22 | 2006-10-04 | ヘンリー エム.ジャクソン ファウンデイション フォー ザ アドバンスメント オブ ミリタリー メディスン | 免疫原性構成物の製造のための新規シアン化試薬を使った可溶性炭水化物の活性化方法 |
GB9326253D0 (en) | 1993-12-23 | 1994-02-23 | Smithkline Beecham Biolog | Vaccines |
ATE231733T1 (de) | 1994-01-21 | 2003-02-15 | Powderject Vaccines Inc | Gasbetätigtes element zum austragen von genmaterial |
WO1995024176A1 (fr) | 1994-03-07 | 1995-09-14 | Bioject, Inc. | Dispositif de remplissage d'ampoule |
US5466220A (en) | 1994-03-08 | 1995-11-14 | Bioject, Inc. | Drug vial mixing and transfer device |
US5648240A (en) | 1994-05-24 | 1997-07-15 | Texas A&M University | MHC II analog from Staphylococcus aureus |
US5505947A (en) | 1994-05-27 | 1996-04-09 | The University Of North Carolina At Chapel Hill | Attenuating mutations in Venezuelan Equine Encephalitis virus |
EP1167377B2 (fr) | 1994-07-15 | 2012-08-08 | University of Iowa Research Foundation | Oliogonucléotides immunomodulateurs |
US6008341A (en) | 1994-08-22 | 1999-12-28 | The Provost, Fellows And Scholars Of The College Of The Holy And Undivided Trinity Of Queen Elizabeth Near Dublin | S. aureus fibrinogen binding protein gene |
US5599302A (en) | 1995-01-09 | 1997-02-04 | Medi-Ject Corporation | Medical injection system and method, gas spring thereof and launching device using gas spring |
GB9502879D0 (en) | 1995-02-14 | 1995-04-05 | Oxford Biosciences Ltd | Particle delivery |
UA56132C2 (uk) | 1995-04-25 | 2003-05-15 | Смітклайн Бічем Байолоджікалс С.А. | Композиція вакцини (варіанти), спосіб стабілізації qs21 відносно гідролізу (варіанти), спосіб приготування композиції вакцини |
US6696065B1 (en) | 1995-05-04 | 2004-02-24 | Aventis Pastuer Limited | Acellular pertussis vaccines and methods of preparation thereof |
US5730723A (en) | 1995-10-10 | 1998-03-24 | Visionary Medical Products Corporation, Inc. | Gas pressured needle-less injection device and method |
GB9521146D0 (en) | 1995-10-16 | 1995-12-20 | Smithkline Beecham Plc | Novel compounds |
JPH11514870A (ja) | 1995-10-16 | 1999-12-21 | スミスクライン・ビーチャム・パブリック・リミテッド・カンパニー | 新規な唾液結合タンパク質 |
US6737248B2 (en) | 1996-01-05 | 2004-05-18 | Human Genome Sciences, Inc. | Staphylococcus aureus polynucleotides and sequences |
US5893397A (en) | 1996-01-12 | 1999-04-13 | Bioject Inc. | Medication vial/syringe liquid-transfer apparatus |
GB9607549D0 (en) | 1996-04-11 | 1996-06-12 | Weston Medical Ltd | Spring-powered dispensing device |
ES2252785T3 (es) | 1996-05-16 | 2006-05-16 | THE TEXAS A&M UNIVERSITY SYSTEM | Composiciones proteinicas fijadoras de colageno y metodos de utilizacion. |
ZA975326B (en) | 1996-06-18 | 1998-01-14 | Alza Corp | Device and method for enhancing transdermal flux of agents being delivered or sampled. |
SE9602496D0 (sv) | 1996-06-20 | 1996-06-20 | Bengt Guss | Method and means for producing a fibrinogen binding protein and its use in biotechnology |
US6294177B1 (en) | 1996-09-11 | 2001-09-25 | Nabi | Staphylococcus aureus antigen-containing whole cell vaccine |
US5980898A (en) | 1996-11-14 | 1999-11-09 | The United States Of America As Represented By The U.S. Army Medical Research & Material Command | Adjuvant for transcutaneous immunization |
ES2195190T3 (es) | 1996-12-20 | 2003-12-01 | Alza Corp | Dispositivo y metodo para mejorar el flujo de agente transdermico. |
US5811407A (en) | 1997-02-19 | 1998-09-22 | The University Of North Carolina At Chapel Hill | System for the in vivo delivery and expression of heterologous genes in the bone marrow |
US5993412A (en) | 1997-05-19 | 1999-11-30 | Bioject, Inc. | Injection apparatus |
US6610293B1 (en) | 1997-06-16 | 2003-08-26 | The Henry M. Jackson Foundation For The Advancement Of Military Medicine | Opsonic and protective monoclonal and chimeric antibodies specific for lipoteichoic acid of gram positive bacteria |
CA2310217A1 (fr) | 1997-11-26 | 1999-06-03 | Inhibitex, Inc. | Proteines liant la matrice extracellulaire issues du staphilococcus aureus |
NZ504894A (en) | 1997-12-02 | 2002-12-20 | Powderject Vaccines Inc | Crystalline vaccine and adjuvant compositions jointly and separately administered to animals using a transdermal or transmucosally delivery technique |
US7323179B2 (en) * | 1997-12-19 | 2008-01-29 | Naomi Balaban | Methods and compositions for the treatment and prevention of Staphylococcus and other bacterial infections |
IT1298087B1 (it) | 1998-01-08 | 1999-12-20 | Fiderm S R L | Dispositivo per il controllo della profondita' di penetrazione di un ago, in particolare applicabile ad una siringa per iniezioni |
GB9806762D0 (en) * | 1998-03-31 | 1998-05-27 | Neutec Pharma Plc | Treatment and diagnosis of staphylococcal infections |
DE69941454D1 (de) | 1998-07-10 | 2009-11-05 | U S Medical Res Inst Of Infect | Impfstoff gegen staphylokokken-vergiftung |
ATE395931T1 (de) * | 1998-07-15 | 2008-06-15 | Brigham & Womens Hospital | Polysaccharid-impfstoff gegen staphylokokken infektionen |
CA2341018C (fr) | 1998-08-31 | 2012-07-31 | The Provost Fellows And Scholars Of The College Of The Holy And Undivided Trinity Of Queen Elizabeth Near Dublin | Polypeptides et polynucleotides issus du staphylocoque negatif quant a la coagulase |
CA2341177A1 (fr) | 1998-08-31 | 2000-03-09 | Inhibitex, Inc. | Procede d'immunotherapie contre les infections staphylococciques comprenant la selection des donneurs et la stimulation des donneurs |
US6703025B1 (en) * | 1998-08-31 | 2004-03-09 | Inhibitex, Inc. | Multicomponent vaccines |
ES2322409T3 (es) * | 1998-08-31 | 2009-06-19 | Inhibitex, Inc. | Vacunas multicomponentes contra staphylococcus aureus. |
ES2321892T3 (es) | 1998-09-14 | 2009-06-12 | Nabi Biopharmaceuticals | Composiciones de beta-glucanos e inmunoglobulinas especificas. |
US6319224B1 (en) | 1999-08-20 | 2001-11-20 | Bioject Medical Technologies Inc. | Intradermal injection system for injecting DNA-based injectables into humans |
US6494865B1 (en) | 1999-10-14 | 2002-12-17 | Becton Dickinson And Company | Intradermal delivery device including a needle assembly |
AU1478301A (en) | 1999-11-09 | 2001-06-06 | Glaxo Group Limited | Staphylococcus epidermidis nucleic acids and proteins |
SE0000514D0 (sv) | 2000-02-17 | 2000-02-17 | Biostapro Ab | A 52 kDa protein from coagulase negative staphylococci and fragments |
GB0014907D0 (en) | 2000-06-20 | 2000-08-09 | Univ Sheffield | Antigenic polypeptides |
US20020051793A1 (en) * | 2000-09-12 | 2002-05-02 | Drabick Joseph J. | Lipoteichoic acid immunogenic compositions and methods of making and using thereof |
AT410798B (de) | 2001-01-26 | 2003-07-25 | Cistem Biotechnologies Gmbh | Verfahren zur identifizierung, isolierung und herstellung von antigenen gegen ein spezifisches pathogen |
US20020169288A1 (en) | 2001-03-15 | 2002-11-14 | Magnus Hook | Collagen-binding adhesin from staphylococcus epidermidis and method of use |
GB0107661D0 (en) | 2001-03-27 | 2001-05-16 | Chiron Spa | Staphylococcus aureus |
EP2320233A1 (fr) | 2001-06-15 | 2011-05-11 | Inhibitex, Inc. | Anticorps monoclonaux et polyclonaux à réaction croisée qui reconnaissent des protéines de surface de staphylocoques à coagulase négative et de staphylocoques dores |
CA2351018A1 (fr) * | 2001-07-09 | 2003-01-09 | Universite De Sherbrooke | Vaccin a adn contre staphylococcus aureus |
CA2453937C (fr) | 2001-08-02 | 2013-05-14 | University Of Sheffield | Polypeptides antigeniques |
US20030113350A1 (en) * | 2001-09-19 | 2003-06-19 | Fattom Ali I. | Glycoconjugate vaccines for use in immune-compromised populations |
US7157443B2 (en) | 2001-12-11 | 2007-01-02 | Merck & Co., Inc. | Staphylococcus aureus exopolysaccharide and process |
CA2478029A1 (fr) | 2002-03-05 | 2003-09-18 | Inhibitex, Inc. | Anticorps monoclonaux et polyclonaux reconnaissant des proteines staphylocoques a coagulase negative |
ES2648046T3 (es) * | 2002-11-12 | 2017-12-28 | The Brigham And Women's Hospital, Inc. | Vacuna de polisacárido para infecciones estafilocócicas |
AU2003290867A1 (en) | 2002-11-12 | 2004-06-03 | The Brigham And Women's Hospital, Inc. | Methods and products for treating staphylococcal infections |
CN1787839B (zh) * | 2003-03-07 | 2011-09-28 | 惠氏控股公司 | 用于抗医院内感染的免疫的多糖-葡萄球菌表面粘附素载体蛋白缀合物 |
EP2305294B1 (fr) | 2004-09-22 | 2015-04-01 | GlaxoSmithKline Biologicals SA | Composition immunogène pour la vaccination contre des staphylocoques |
EA201001478A1 (ru) * | 2008-04-16 | 2011-06-30 | Глаксосмитклайн Байолоджикалс С.А. | Вакцина |
TWI469789B (zh) | 2009-06-22 | 2015-01-21 | Wyeth Llc | 金黃色葡萄球菌抗原之免疫原性組合物 |
EP2654784B1 (fr) | 2010-12-22 | 2016-12-07 | Wyeth LLC | Compositions immunogènes stables d'antigènes de staphylococcus aureus |
-
2005
- 2005-09-20 EP EP10010648.3A patent/EP2305294B1/fr not_active Revoked
- 2005-09-20 MX MX2007003400A patent/MX2007003400A/es active IP Right Grant
- 2005-09-20 CA CA2983954A patent/CA2983954C/fr active Active
- 2005-09-20 MX MX2007003402A patent/MX2007003402A/es active IP Right Grant
- 2005-09-20 EP EP10010422.3A patent/EP2298340B1/fr active Active
- 2005-09-20 CN CN201210154263.9A patent/CN102657855B/zh active Active
- 2005-09-20 AU AU2005287502A patent/AU2005287502B2/en not_active Ceased
- 2005-09-20 CA CA002580137A patent/CA2580137A1/fr not_active Abandoned
- 2005-09-20 WO PCT/EP2005/010199 patent/WO2006032475A2/fr active Application Filing
- 2005-09-20 ES ES10010422.3T patent/ES2472441T3/es active Active
- 2005-09-20 CN CN2005800396900A patent/CN101128215B/zh active Active
- 2005-09-20 CA CA002584290A patent/CA2584290A1/fr not_active Abandoned
- 2005-09-20 AU AU2005287532A patent/AU2005287532B2/en not_active Ceased
- 2005-09-20 KR KR1020137019530A patent/KR101505496B1/ko active IP Right Grant
- 2005-09-20 NZ NZ582441A patent/NZ582441A/en not_active IP Right Cessation
- 2005-09-20 BR BR122016029840-0A patent/BR122016029840B1/pt active IP Right Grant
- 2005-09-20 EP EP05786195A patent/EP1793849A2/fr not_active Withdrawn
- 2005-09-20 KR KR1020077008929A patent/KR101359930B1/ko active IP Right Grant
- 2005-09-20 WO PCT/EP2005/010260 patent/WO2006032500A2/fr active Application Filing
- 2005-09-20 BR BRPI0515516-9A patent/BRPI0515516B1/pt active IP Right Grant
- 2005-09-20 ES ES15153661T patent/ES2730275T3/es active Active
- 2005-09-20 JP JP2007531712A patent/JP2008513406A/ja active Pending
- 2005-09-20 JP JP2007531718A patent/JP2008513409A/ja active Pending
- 2005-09-20 CA CA2580103A patent/CA2580103C/fr active Active
- 2005-09-20 US US11/575,672 patent/US20080095777A1/en not_active Abandoned
- 2005-09-20 EP EP10000300A patent/EP2181714A3/fr not_active Withdrawn
- 2005-09-20 BR BRPI0515520-7A patent/BRPI0515520A/pt not_active IP Right Cessation
- 2005-09-20 NZ NZ593693A patent/NZ593693A/xx not_active IP Right Cessation
- 2005-09-20 ES ES10010739.0T patent/ES2540771T3/es active Active
- 2005-09-20 EP EP10010739.0A patent/EP2305295B1/fr active Active
- 2005-09-20 NZ NZ553775A patent/NZ553775A/en not_active IP Right Cessation
- 2005-09-20 EP EP05786253A patent/EP1804833A2/fr not_active Withdrawn
- 2005-09-20 EP EP15153661.2A patent/EP2893938B1/fr active Active
- 2005-09-20 WO PCT/EP2005/010184 patent/WO2006032472A2/fr active Application Filing
- 2005-09-20 KR KR1020127029529A patent/KR101508563B1/ko active IP Right Grant
- 2005-09-20 EP EP05791856A patent/EP1791559A2/fr not_active Ceased
- 2005-09-20 US US11/575,694 patent/US20080085289A1/en not_active Abandoned
- 2005-09-20 EP EP10011107A patent/EP2305296A1/fr not_active Ceased
- 2005-09-20 KR KR1020077008932A patent/KR20070058631A/ko not_active Application Discontinuation
- 2005-09-20 ES ES10010648.3T patent/ES2540770T3/es active Active
- 2005-09-20 RU RU2007110029/10A patent/RU2402347C2/ru not_active IP Right Cessation
- 2005-09-20 AU AU2005287505A patent/AU2005287505A1/en not_active Abandoned
- 2005-09-20 NZ NZ553776A patent/NZ553776A/en not_active IP Right Cessation
-
2007
- 2007-03-08 IL IL181825A patent/IL181825A0/en unknown
- 2007-03-14 IL IL181920A patent/IL181920A/en active IP Right Grant
- 2007-03-16 ZA ZA2007/02224A patent/ZA200702224B/en unknown
- 2007-03-27 NO NO20071609A patent/NO20071609L/no not_active Application Discontinuation
- 2007-03-27 NO NO20071610A patent/NO20071610L/no not_active Application Discontinuation
- 2007-04-11 MA MA29821A patent/MA28994B1/fr unknown
- 2007-04-11 MA MA29822A patent/MA28995B1/fr unknown
- 2007-04-18 IL IL182639A patent/IL182639A0/en unknown
- 2007-10-25 HK HK11109985.5A patent/HK1155658A1/xx unknown
-
2010
- 2010-04-15 US US12/662,413 patent/US20110008385A1/en not_active Abandoned
-
2012
- 2012-01-19 JP JP2012009225A patent/JP5775005B2/ja active Active
- 2012-11-20 IL IL223141A patent/IL223141B/en active IP Right Grant
-
2015
- 2015-03-18 US US14/662,003 patent/US20150328302A1/en not_active Abandoned
- 2015-05-07 JP JP2015094545A patent/JP2015166365A/ja active Pending
-
2017
- 2017-09-15 JP JP2017177214A patent/JP6594385B2/ja active Active
-
2018
- 2018-07-26 US US16/046,505 patent/US10548963B2/en active Active
-
2019
- 2019-12-16 US US16/716,352 patent/US20200179504A1/en not_active Abandoned
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
FR22C1008I2 (fr) | Composition immunogène | |
MA28995B1 (fr) | Composition immunogene | |
ATE352316T1 (de) | Immunogene zusammensetzung | |
ATE359295T1 (de) | Immunogene zusammensetzungen | |
ITMI20041252A1 (it) | Composizioni perfluoroelastomeriche | |
NO20053161D0 (no) | Mikrobedrepende sammensetning. | |
ATE509627T1 (de) | Zusammensetzungen mit nebivolol | |
ATE414693T1 (de) | Neuartige cis-imidazoline | |
FI20040156A0 (fi) | Hydraulivasara | |
NO20055686D0 (no) | Sammensetning | |
DE602005016978D1 (de) | Quecksilberfreisetzende Zusammensetzungen | |
DK2067854T3 (da) | Kloningsvektorer | |
DE602005017191D1 (de) | Geruchsreduzierte waschstück-zusammensetzung | |
DE602005023936D1 (de) | Kühlmittelzusammensetzung | |
DE602005024486D1 (de) | Anthrapyridonfarbstoffe | |
DE602005002680D1 (de) | Härtbare Organopolysiloxanzusammensetzung | |
DE602005019013D1 (de) | Tonerzusammensetzung | |
FR2871686B1 (fr) | Composition anti-decoloration | |
GB0421079D0 (en) | Immunogenic composition | |
NO20042027L (no) | Oral composition | |
SE0400205D0 (sv) | Composition | |
GB0421081D0 (en) | Immunogenic composition | |
GB0421078D0 (en) | Immunogenic composition | |
GB0421082D0 (en) | Immunogenic composition | |
DE602005012963D1 (de) | Hydratisierende zusammensetzung |